New investigation highlights preclinical efficacy of at combination of immune checkpoint inhibitors and therapies targeting myeloid-derived suppressor cells in advanced prostate cancer.
Browsing: Taxonomy > Immunotherapy
What advances have been made in immune therapy for renal cell carcinoma? Discover what the experts say in this opinion article from Future Oncology.
Where is the field of melanoma therapy heading? In this editorial article from Future Oncology find out more about emerging therapies and the improvements being made to current drugs.
Researchers have identified a mutation that enables melanoma cells to remain undetected by the immune system.
What are the current immunotherapeutic options for colorectal cancer? Find out in this review article from Immunotherapy.
To mark Rare Disease Day, Oncology Central brings you an exclusive opinion piece written by two of the principal investigators of a pivotal immunotherapy clinical trial designed specifically for rare cancer patients.
Following the continuing evolution of cancer immunotherapy, this featured article discusses how image-guided, minimally invasive therapies and immuno-oncology agents may be combined – could there be resultant synergy between these two modalities?
In this article from Nanomedicine, the potency of trifunctional nanoparticles that target and activate CD8+ dendritic cells is explored.
Could dendritic cell vaccines be a promising therapeutic strategy for advanced melanoma? Read more in this article from Melanoma Management.
James Gulley of the National Cancer Institute talks to us about his work developing cancer immunotherapies, his insights into the impact of this modality in prostate cancer and his hopes for the future of the field.